Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 3, 2002, Pages 802-809

  Galbiati, Elisabetta ^a   Caruso, Paola Lorenza ^a   Amari, Gabriele ^a   Armani, Elisabetta ^a   Ghirardi, Silvia ^a   Delcanale, Maurizio ^a   Civelli, Maurizio ^a,b  

^a Department of Pharmacology ^*  (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYL 4 [[4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL]METHYL] 2H 1 BENZOPYRAN 7 OL; BENZOPYRAN DERIVATIVE; CHF 4056; CHOLESTEROL; OSTEOCALCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; BONE ATROPHY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; LUMBAR SPINE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; UTERUS;

ANIMALS; BENZOPYRANS; BONE DENSITY; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHIL PEROXIDASE; ESTRADIOL CONGENERS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYL ESTRADIOL; FEMALE; HUMANS; OVARIECTOMY; PEROXIDASES; PIPERIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERUS;

EID: 0036175904     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.3.802     Document Type: Article

References (40)

1. Basic concepts to analyze binding data using personal computers: The "RECEPT" program
2. Levormeloxifene, a new partial estrogen receptor agonist demonstrates antiresorptive and antiatherogenic properties in postmenopausal women
3. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
4. The estradiol-stimulated lipoprotein receptor of rat liver
5. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer
6. 50) of an enzymatic reaction
7. Raloxifene: A review of its use in postmenopausal osteoporosis
8. Evaluating the benefit and the risks of postmenopausal hormone replacement therapy
9. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
10. Pharmacologic and biological properties of droloxifene, a new antiestrogen
11. Tissue-selective actions of estrogen analogs
12. Hormone therapy to prevent disease and prolong life in postmenopausal women
13. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats
14. Molecular determinants of tissue selectivity in estrogen receptor modulators
15. Postmenopausal hormone therapy and mortality
16. Estrogen receptor β: A new dimension in estrogen mechanism of action
17. Hormone replacement therapy and breast cancer
18. Effect of anti-estrogens on bone in castrated and intact female rats
19. The ovariectomized rat model of postmenopausal bone loss
20. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
21. The estrogen receptor β subtype; a novel mediator of estrogen action in neuroendocrine system
22. Sex steroids in the pathogenesis and prevention of osteoporosis
23. Prevention of spinal osteoporosis in oophorectomized women
24. Benefits and risks of estrogen replacement therapy
25. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
26. Uterine peroxidase as a marker for estrogen action
27. Differentiation between vasculoprotective and uterotropic effects of ligands with different binding affinities to estrogen receptors α and β
28. Selective estrogen receptor modulators. A look ahead
29. Effect of levormeloxifene, a partial estrogen receptor agonist, on serum cholesterol, osteocalcin and bone in the ovariectomized rat
30. Hormone and DNA-binding mechanisms of the recombinant human estrogen receptor
31. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma
32. Oestrogen replacement therapy and cardiovascular disease
33. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis
34. Raloxifene, tamoxifen, nafoxidine, or estrogens effects on reproductive and nonreproductive tissues in ovariectomized rats
35. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice
36. Exogenous hormones in the etiology of cancer in women
37. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
38. A kinetic assay for eosinophil peroxidase activity in eosinophils and eosinophil conditioned media
39. Increased risk of endometrial carcinoma among users of conjugated estrogens
40. Hormone replacement and cardiovascular risk factors